GET DAILY SIGNALSReplimune Group (REPL) Shares Climb +31% as TUDRIQEV Launch Gains Traction
Key Takeaways
- REPL shares have climbed roughly 31% over the past 30 days, from about $13.00 to near $17, as Replimune's first commercial launch gained early momentum.
- The move is anchored by the U.S. launch of TUDRIQEV (vusolimogene oderparepvec), the company's oncolytic immunotherapy for advanced melanoma, which was first delivered to patients on October 6.
- Over the last quarter, the stock has risen more than threefold from its late-July lows, following FDA accelerated approval of TUDRIQEV.
- Fiscal second-quarter 2027 results reported on October 28 detailed strong early launch engagement, with more than 15 institutions prescribing the therapy.
- Wall Street remains constructive: the average analyst rating is Buy with a consensus 12-month price target near $19.50, and at least one firm has raised its target to $29.
- Key watchpoints ahead include commercial launch execution, reimbursement coverage, and progress on confirmatory and pipeline trials.
- For more detail on REPL's Price Targets, Earnings, and Forecast, explore the dedicated pages.
Replimune Group (REPL) Company Overview and Market Position
Replimune Group, Inc. is a Massachusetts-based biotechnology company that develops oncolytic immunotherapies designed to activate the immune system against cancer. Founded in 2015 and headquartered in Woburn, the company's proprietary RPx platform is built on an engineered herpes simplex virus type 1 (HSV-1) backbone intended to trigger immunogenic tumor cell death and a systemic anti-tumor immune response.
The company's lead product, TUDRIQEV (vusolimogene oderparepvec), is approved in the United States in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease has progressed on a PD-1-blocking regimen. The company is also advancing RP2 (sturlimgene erparepvec) in metastatic uveal melanoma. Investors follow REPL for its transition from a clinical-stage developer into a commercial-stage oncology company, its positioning in the emerging oncolytic immunotherapy field, and the trajectory of its first product launch. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Replimune Group (REPL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, REPL has advanced approximately 31%, moving from a closing price of about $13.00 in late September to roughly $17 in late October. The rally was not linear: shares pulled back to around $10.86 in mid-October before surging in the final stretch of the month.
The quarterly picture is even more pronounced. From a late-July low near $5.41, REPL has risen more than 200%, effectively tripling in value. That extraordinary move reflects a binary regulatory outcome: the stock sold off sharply in late July ahead of an FDA advisory committee meeting, then recovered and re-rated higher after the agency granted accelerated approval in early August, transitioning the company to its commercial phase.
What Drove REPL Stock Price in the Last 30 Days
The dominant catalyst over the past month has been the early execution of Replimune's first commercial launch. TUDRIQEV was first delivered to patients for advanced melanoma on October 6, and the company has reported prescriptions from more than 15 institutions, signaling rapid formulary access and account engagement.
The sharpest single-day move came around the company's fiscal second-quarter 2027 earnings report on October 28. Management detailed strong initial launch traction, and the market responded by pushing shares up more than 20% in a single session. Analyst activity reinforced the optimism, with Jefferies raising its price target to $29 from $24 and maintaining a Buy rating. Sentiment has also been supported by the broader de-risking of the regulatory story now that the product is approved and commercially available.
What Drove REPL Stock Performance Over the Last Quarter
The quarterly trend is defined by a single, high-stakes regulatory milestone. In late July, the stock fell sharply to roughly $5.35 when FDA briefing documents raised questions about the single-arm IGNYTE trial data supporting the biologics license application. A favorable 10-3 advisory committee vote on July 30 reversed that move, and the FDA subsequently granted accelerated approval of TUDRIQEV in early August.
That approval transformed Replimune from a pre-revenue biotech with a going-concern disclosure into a company with an approved oncology product and a commercial launch underway. The re-rating reflects reduced regulatory risk, the establishment of a U.S. sales infrastructure, and renewed confidence in the RPx platform's broader potential across melanoma and other skin cancers.
REPL Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important factors for REPL are commercial rather than regulatory. Investors will monitor the pace of TUDRIQEV adoption, prescription trends, reimbursement and payer coverage, and the company's ability to convert early account engagement into sustained revenue. Because the approval was granted under the accelerated pathway, continued marketing will also depend on confirmatory trial results verifying clinical benefit.
Additional watchpoints include financial discipline and cash runway, progress on the RP2 program in metastatic uveal melanoma, and any expansion of the TUDRIQEV label into additional skin cancer indications. Competitive developments in the broader immuno-oncology and oncolytic therapy space, along with analyst target revisions, will continue to shape sentiment.
Exploring AI Trading Bots for Portfolio Insights
In my own process, I turn to Tickeron’s AI Trading Bots to review how automated strategies are currently tracking stocks like REPL. The platform highlights top-performing bots across different timeframes and approaches, which can offer an additional lens when evaluating momentum in names undergoing major transitions. This helps complement fundamental analysis without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
REPL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for REPL turned positive on October 26, 2026. Looking at past instances where REPL's MACD turned positive, the stock continued to rise in 47 of 50 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on REPL as a result. In 68 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +28.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 184 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for REPL crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REPL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.323) is normal, around the industry mean (3.151). P/E Ratio (-5.098) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of oncolytic immunotherapies
Industry Biotechnology
Advertisement